Fraxinus excelsior

Fraxinus excelsior (common ash) contains active secoiridoid glycosides, particularly oleuropein and nuzhenide in its seeds, which modulate glucose metabolism by inhibiting intestinal alpha-glucosidase activity and improving insulin sensitivity. Clinical evidence supports its seed extract for reducing postprandial blood glucose spikes, while leaf preparations show antihypertensive effects likely mediated through ACE inhibition and calcium channel antagonism.

Origin & History

Fraxinus excelsior, commonly known as common ash or European ash, is a deciduous tree native to Europe and parts of Asia, belonging to the Oleaceae family. The plant's leaves, seeds, and bark are used medicinally, with commercial extracts typically prepared as standardized ethanol extracts from leaves (FraxiPure™) or seeds (Glucevia®).

Historical & Cultural Context

Fraxinus excelsior has long-term use in European phytotherapy for conditions including inflammation, hypertension, and metabolic issues. Traditional applications also include bark extracts for antimalarial purposes, with modern studies confirming in vitro activity against Plasmodium falciparum.

Health Benefits

• Improved glucose tolerance: Seed extract reduced post-meal glucose AUC by 28.2% in overweight adults (moderate evidence, PMID: 24877717)
• Blood pressure support: Aqueous leaf extract reduced systolic blood pressure by 13.5% in hypertensive rats at 20 mg/kg (preliminary evidence, animal studies only)
• Enhanced metabolic health: Increased adiponectin:leptin ratio and reduced fat mass in human trial (moderate evidence, PMID: 24877717)
• Anti-inflammatory activity: Leaf compounds reduced TNF-α and IL-6 comparable to dexamethasone in vitro (preliminary evidence, cell studies only)
• Diuretic effects: Increased urinary electrolyte excretion and glomerular filtration rate in rats (preliminary evidence, animal studies only)

How It Works

The secoiridoid glycosides in Fraxinus excelsior seeds, including nuzhenide and GI3, inhibit intestinal alpha-glucosidase enzymes, slowing carbohydrate digestion and blunting postprandial glucose absorption. Leaf-derived compounds, including fraxin (a coumarin glycoside) and hydroxycinnamic acid derivatives, appear to inhibit angiotensin-converting enzyme (ACE) and antagonize voltage-gated calcium channels in vascular smooth muscle, contributing to vasodilation. Additionally, polyphenolic constituents may enhance GLUT4 translocation and improve peripheral insulin signaling through AMPK pathway activation.

Scientific Research

Human clinical evidence is limited to two RCTs: a 90-day safety study with 100 healthy volunteers showing no adverse effects at 1000 mg/day FraxiPure™ (PMID: 23201448), and a 3-week crossover trial in 22 overweight adults demonstrating significant glucose-lowering effects with Glucevia® seed extract (PMID: 24877717). No meta-analyses or large-scale human trials exist for cardiovascular or anti-inflammatory effects.

Clinical Summary

A randomized, double-blind, placebo-controlled crossover trial (PMID: 24877717) in overweight adults demonstrated that Fraxinus excelsior seed extract reduced postprandial glucose area under the curve (AUC) by 28.2%, representing the strongest human clinical evidence for this ingredient. Animal studies in hypertensive rat models showed that aqueous leaf extract at 20 mg/kg reduced systolic blood pressure by approximately 13.5%, though these findings have not yet been replicated in human trials. The seed extract evidence is classified as moderate quality given its controlled design, but sample sizes remain small and long-term safety data in humans are lacking. Overall, the evidence base is promising but preliminary, particularly for the antihypertensive applications.

Nutritional Profile

Fraxinus excelsior (European Ash) contains bioactive compounds concentrated across seeds, leaves, and bark. Seeds contain secoiridoid glycosides including nuzhenide (primary bioactive, ~0.5-2% dry weight) and GI3 (nuzhenide-11-methyl oleuropein), which are responsible for glucose-lowering effects. Leaves are rich in hydroxycoumarins, primarily fraxin and esculin (0.1-0.5% dry weight), alongside flavonoids including rutin (~0.3-0.8% dry weight) and quercetin derivatives. Polyphenolic content includes chlorogenic acids and caffeic acid esters (~1-3% dry weight in leaf extracts). Leaves also contain iridoids (oleoside-type), mannitol (~5-10% dry weight, a sugar alcohol with prebiotic properties), and small amounts of tannins. Bark contains fraxetin (a coumarin), syringin (a phenylpropanoid glycoside), and lignans. Mineral content in leaves includes potassium (~15-20 mg/g dry weight), calcium (~12-18 mg/g dry weight), and magnesium (~3-5 mg/g dry weight). Vitamin C is present in modest amounts (~20-40 mg/100g fresh leaf). Fiber content is notable in seeds (~15-25% dry weight), contributing to the delayed glucose absorption mechanism. Bioavailability of secoiridoids is enhanced by gut microbiota hydrolysis; polyphenol absorption is moderate (~10-30%) and improved with food matrix co-ingestion.

Preparation & Dosage

Clinically studied doses include 1000 mg/day of FraxiPure™ leaf extract for 90 days (safety) or 1000 mg/day Glucevia® seed extract (3 × 333 mg capsules) for 3 weeks (metabolic effects). Preclinical studies used 20-200 mg/kg in rats. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium picolinate, Gymnema sylvestre, Bitter melon extract, Alpha-lipoic acid, Cinnamon extract

Safety & Interactions

Fraxinus excelsior is generally considered well-tolerated at studied doses, with no serious adverse events reported in available clinical trials, though comprehensive human safety data remain limited. Due to its alpha-glucosidase inhibitory activity, concurrent use with antidiabetic medications such as metformin, sulfonylureas, or acarbose may potentiate hypoglycemic effects, warranting blood glucose monitoring. Its potential ACE-inhibitory and vasodilatory properties suggest caution when combined with antihypertensive drugs, as additive blood pressure lowering could occur. Insufficient data exist to establish safety during pregnancy or lactation, so use should be avoided in these populations until further evidence is available.